BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38427584)

  • 21. Can a machine-learning model improve the prediction of nodal stage after a positive sentinel lymph node biopsy in breast cancer?
    Madekivi V; Boström P; Karlsson A; Aaltonen R; Salminen E
    Acta Oncol; 2020 Jun; 59(6):689-695. PubMed ID: 32148141
    [No Abstract]   [Full Text] [Related]  

  • 22. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy.
    Jeruss JS; Newman LA; Ayers GD; Cristofanilli M; Broglio KR; Meric-Bernstam F; Yi M; Waljee JF; Ross MI; Hunt KK
    Cancer; 2008 Jun; 112(12):2646-54. PubMed ID: 18442039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes.
    Cipolla C; Lupo S; Grassi N; Battaglia MC; Mesi C; Scandurra G; Gebbia V; Valerio MR
    Anticancer Res; 2024 May; 44(5):2047-2053. PubMed ID: 38677748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower lymph node yield in axillary lymph node dissection specimens in breast cancer patients receiving neoadjuvant chemotherapy: Quality concern or treatment effect?
    Ozao-Choy J; Moazzez A; Dauphine C
    Breast J; 2021 Dec; 27(12):851-856. PubMed ID: 34877726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.
    Chen P; Zhao T; Bi Z; Zhang ZP; Xie L; Liu YB; Song XG; Song XR; Wang CJ; Wang YS
    Future Oncol; 2021 Jul; 17(19):2449-2460. PubMed ID: 33878939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
    Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
    Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nomogram to predict non-sentinel lymph node metastasis in patients with initial cN+ breast cancer that downstages to cN0 after neoadjuvant chemotherapy.
    Cheng M; Zhuang X; Zhang L; Zhu T; Lin Y; Yang M; Ji F; Yang C; Gao H; Wang K
    J Surg Oncol; 2020 Sep; 122(3):373-381. PubMed ID: 32436217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer?
    Osorio-Silla I; Gómez Valdazo A; Sánchez Méndez JI; York E; Díaz-Almirón M; Gómez Ramírez J; Rivas Fidalgo S; Oliver JM; Álvarez CM; Hardisson D; Díaz Miguel M; Lobo F; Díaz Domínguez J
    Ann R Coll Surg Engl; 2019 Mar; 101(3):186-192. PubMed ID: 30421628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Axillary Ultrasound Identify Node Positive Patients Who can Avoid an Axillary Dissection After Neoadjuvant Chemotherapy?
    Turza L; Mohamed Ali AM; Mylander WC; Cattaneo I; Pack D; Rosman M; Tafra L; Jackson RS
    J Surg Res; 2024 Jan; 293():625-631. PubMed ID: 37837818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.
    Kantor O; Sipsy LM; Yao K; James TA
    Ann Surg Oncol; 2018 May; 25(5):1304-1311. PubMed ID: 29368152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study.
    van Nijnatten TJA; Simons JM; Smidt ML; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef K; Koppert LB; Luiten EJT
    Clin Breast Cancer; 2017 Aug; 17(5):399-402. PubMed ID: 28487053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.
    Jin X; Jiang YZ; Chen S; Shao ZM; Di GH
    Sci Rep; 2016 Aug; 6():32585. PubMed ID: 27576704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
    Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
    Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multifactor artificial intelligence model assists axillary lymph node surgery in breast cancer after neoadjuvant chemotherapy: multicenter retrospective cohort study.
    Zhu T; Huang YH; Li W; Zhang YM; Lin YY; Cheng MY; Wu ZY; Ye GL; Lin Y; Wang K
    Int J Surg; 2023 Nov; 109(11):3383-3394. PubMed ID: 37830943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation.
    Takei H; Yoshida T; Kurosumi M; Inoue K; Matsumoto H; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Kubo K; Oba H; Nagai S; Tabei T
    Int J Clin Oncol; 2013 Jun; 18(3):547-53. PubMed ID: 22588780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.